Alloxan and streptozotocin are toxic glucose analogues that selectively target pancreatic beta cells. Alloxan enters beta cells via the GLUT2 transporter and generates reactive oxygen species (ROS) through redox cycling with its reduction product, dialuric acid. This leads to oxidative stress, mitochondrial damage, and beta cell death, causing insulin-dependent diabetes. Alloxan also inhibits glucose-induced insulin secretion by blocking glucokinase, a key glucose sensor in beta cells. Streptozotocin, an alkylating agent, enters beta cells via the same transporter and causes DNA damage, leading to beta cell death and diabetes. Both agents cause similar blood glucose and insulin responses, resulting in a type 1-like diabetes. Alloxan toxicity is mediated by ROS, particularly hydroxyl radicals, while streptozotocin toxicity is due to DNA alkylation. The mechanisms differ in their underlying pathways but result in similar clinical outcomes. Alloxan's toxicity is also influenced by its interaction with thiols, which can mitigate its effects. Streptozotocin's toxicity is linked to DNA damage and mitochondrial dysfunction. Both agents are used in diabetes research to induce insulin-dependent diabetes, with streptozotocin being more stable and less toxic than alloxan. Understanding these mechanisms is crucial for developing treatments for diabetes.Alloxan and streptozotocin are toxic glucose analogues that selectively target pancreatic beta cells. Alloxan enters beta cells via the GLUT2 transporter and generates reactive oxygen species (ROS) through redox cycling with its reduction product, dialuric acid. This leads to oxidative stress, mitochondrial damage, and beta cell death, causing insulin-dependent diabetes. Alloxan also inhibits glucose-induced insulin secretion by blocking glucokinase, a key glucose sensor in beta cells. Streptozotocin, an alkylating agent, enters beta cells via the same transporter and causes DNA damage, leading to beta cell death and diabetes. Both agents cause similar blood glucose and insulin responses, resulting in a type 1-like diabetes. Alloxan toxicity is mediated by ROS, particularly hydroxyl radicals, while streptozotocin toxicity is due to DNA alkylation. The mechanisms differ in their underlying pathways but result in similar clinical outcomes. Alloxan's toxicity is also influenced by its interaction with thiols, which can mitigate its effects. Streptozotocin's toxicity is linked to DNA damage and mitochondrial dysfunction. Both agents are used in diabetes research to induce insulin-dependent diabetes, with streptozotocin being more stable and less toxic than alloxan. Understanding these mechanisms is crucial for developing treatments for diabetes.